. Author manuscript; available in PMC: 2020 Apr 1.

Published in final edited form as: Diabetes Obes Metab. 2019 Apr;21(Suppl 2):24–33. doi: 10.1111/dom.13692

Table 1.

Indications for SGLT-2 inhibitors

Where are we now? (41)	Where are we going? (81)
Uncontrolled T2D despite metformin and eGFR > 30 – 60 ml/min/1.73 m² ^†	Uncontrolled T2D despite metformin and eGFR > 30–60 ml/min/1.73 m² ^†
	Controlled T2D and:
	- CVD
	- HF (HFpEF or HFrEF)
	- CKD (eGFR < 60 ml/min/1.73 m², hyperfiltration, albuminuria) HF or CKD without T2D

Abbreviations: CKD: chronic kidney disease, CVD: cardiovascular disease; eGFR: estimated glomerular filtration rate; HF: heart failure; HFpEF: heart failure with preserved ejection fraction; HFrEF: heart failure with reduced ejection fraction; T2D: type 2 diabetes mellitus

^†

if the indication involves glucose-lowering, eGFR threshold depends on SGLT-2 inhibitor and country